INT172963

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.21
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 13
Disease Relevance 12.94
Pain Relevance 2.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Pdgfa) extracellular region (Pdgfa)
Anatomy Link Frequency
paw 2
platelet 2
lung 2
body 1
Pdgfa (Mus musculus)
Pain Link Frequency Relevance Heat
withdrawal 14 100.00 Very High Very High Very High
fibrosis 303 99.62 Very High Very High Very High
intrathecal 28 98.72 Very High Very High Very High
metalloproteinase 4 98.46 Very High Very High Very High
allodynia 4 94.88 High High
Inflammation 79 92.16 High High
Brush evoked pain 40 88.60 High High
Arthritis 32 81.52 Quite High
antagonist 10 80.96 Quite High
cva 3 72.04 Quite High
Disease Link Frequency Relevance Heat
Pulmonary Fibrosis 204 99.62 Very High Very High Very High
Cancer 572 99.50 Very High Very High Very High
Body Weight 13 99.44 Very High Very High Very High
Pancreatic Cancer 57 98.76 Very High Very High Very High
Adhesions 10 98.66 Very High Very High Very High
Severe Combined Immunodeficiency 14 96.80 Very High Very High Very High
Neuropathic Pain 74 94.88 High High
Carcinoma 31 94.36 High High
Targeted Disruption 75 93.60 High High
Arthritis 45 93.36 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Previous studies have shown that treatment with inhibitors of platelet-derived growth factor (PDGF) or vascular endothelial growth factor (VEGF) signaling lowers the IFP of tumors and improve chemotherapy.
Negative_regulation (inhibitors) of platelet-derived growth factor in platelet associated with cancer
1) Confidence 0.21 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2781164 Disease Relevance 0.68 Pain Relevance 0
Previous studies have shown that treatment with inhibitors of platelet-derived growth factor (PDGF) or vascular endothelial growth factor (VEGF) signaling lowers the IFP of tumors and improve chemotherapy.
Negative_regulation (inhibitors) of PDGF in platelet associated with cancer
2) Confidence 0.21 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2781164 Disease Relevance 0.69 Pain Relevance 0
Thus, there is a growing interest in the development of tumor treatment strategies by blocking PDGF/PDGFR function.
Negative_regulation (blocking) of PDGF associated with cancer
3) Confidence 0.20 Published 2007 Journal BMC Cancer Section Abstract Doc Link PMC2234427 Disease Relevance 1.00 Pain Relevance 0
Using mouse models it was shown that inhibition of PDGF signaling reduces interstitial fluid pressure in tumors, and thereby enhances the effect of chemotherapy [11,12].
Negative_regulation (inhibition) of PDGF associated with cancer
4) Confidence 0.20 Published 2007 Journal BMC Cancer Section Body Doc Link PMC2234427 Disease Relevance 0.71 Pain Relevance 0.04
Inhibition of PDGF activity with kinase inhibitors has been demonstrated to significantly reduce lung fibrosis in animal models [47-50].
Negative_regulation (Inhibition) of PDGF in lung associated with fibrosis and pulmonary fibrosis
5) Confidence 0.19 Published 2010 Journal Fibrogenesis Tissue Repair Section Body Doc Link PMC2940818 Disease Relevance 0.97 Pain Relevance 0.20
We used the low molecular weight compound imatinib (Glivec, STI571) as a PDGF receptor tyrosine kinase inhibitor at 100 mg/kg body weight.
Negative_regulation (inhibitor) of PDGF in body associated with body weight
6) Confidence 0.15 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2781164 Disease Relevance 1.30 Pain Relevance 0.08
For example, PGE2, an arachidonic acid metabolite generated by the cyclooxygenase-2 (COX-2) enzyme, is protective in lung fibrosis partly because it downregulates the PDGF-R?
Negative_regulation (downregulates) of PDGF in lung associated with fibrosis and pulmonary fibrosis
7) Confidence 0.14 Published 2010 Journal Fibrogenesis Tissue Repair Section Body Doc Link PMC2940818 Disease Relevance 1.01 Pain Relevance 0.31
1, which also downregulates PDGF-R?
Negative_regulation (downregulates) of PDGF
8) Confidence 0.14 Published 2010 Journal Fibrogenesis Tissue Repair Section Body Doc Link PMC2940818 Disease Relevance 0.96 Pain Relevance 0.31
Among more than 50 known angiogenic factors (including matrix metalloproteinases, adhesion molecules, enzymes, and growth factors), we found that expression levels of PDGF-B, PDGF receptor ?
Negative_regulation (levels) of PDGF associated with metalloproteinase and adhesions
9) Confidence 0.13 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2246237 Disease Relevance 1.22 Pain Relevance 0.24
The anti-tumor activity of SU6668 has been attributed to its antiangiogenic potential arising from its inhibitory effect on the receptor-tyrosine kinase activity of VEGF, FGF, and PDGF.
Negative_regulation (effect) of PDGF associated with cancer
10) Confidence 0.13 Published 2007 Journal BMC Cancer Section Body Doc Link PMC1832206 Disease Relevance 1.98 Pain Relevance 0
Since imatinib mesylate inhibits the PDGF-R kinase activity, it could possibly be a potent therapeutical approach for pancreatic cancer as well.


Negative_regulation (inhibits) of PDGF associated with pancreatic cancer
11) Confidence 0.05 Published 2003 Journal Mol Cancer Section Body Doc Link PMC149419 Disease Relevance 1.33 Pain Relevance 0.04
Consistent with the previous results in mice [24], intrathecal pretreatment with AG17 (100 nmol) significantly attenuated the decrease in the paw withdrawal threshold 7 days after PDGF administration (PDGF-BB + vehicle group, 1.71 ± 0.41, n = 4; PDGF-BB + AG17 group, 9.43 ± 1.13, n = 4; P < 0.001).
Negative_regulation (decrease) of PDGF in paw associated with withdrawal and intrathecal
12) Confidence 0.05 Published 2009 Journal Mol Pain Section Body Doc Link PMC2690582 Disease Relevance 0.54 Pain Relevance 0.71
Consistent with the previous results in mice [24], intrathecal pretreatment with AG17 (100 nmol) significantly attenuated the decrease in the paw withdrawal threshold 7 days after PDGF administration (PDGF-BB + vehicle group, 1.71 ± 0.41, n = 4; PDGF-BB + AG17 group, 9.43 ± 1.13, n = 4; P < 0.001).
Negative_regulation (decrease) of PDGF in paw associated with withdrawal and intrathecal
13) Confidence 0.05 Published 2009 Journal Mol Pain Section Body Doc Link PMC2690582 Disease Relevance 0.54 Pain Relevance 0.72

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox